Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) Novartis (Press Release) 11:43 Fri, 12 Jun
India needs to remain attractive for innovation-led investment: Judith Love, Novartis The Times of India 20:11 Thu, 11 Jun
ASCO: Novartis To Face Challengers In Growing Radiopharmaceutical Space Scrip Pharma Intelligence 19:35 Thu, 11 Jun
Market Outlook: Apple, Novartis, Rio Tinto stand out on momentum trends BNN Bloomberg 16:55 Thu, 11 Jun
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win Clinical Trials Arena 16:21 Thu, 11 Jun
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet Scrip Pharma Intelligence 14:19 Thu, 11 Jun
Orionis Back In Novartis’s Orbit With New Molecular Glue Deal Scrip Pharma Intelligence 14:09 Thu, 11 Jun
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint Novartis (Press Release) 07:04 Thu, 11 Jun
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis BioWorld 21:48 Wed, 10 Jun Article paywall
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines Business Wire (Press Release) 12:03 Wed, 10 Jun
ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space Scrip Pharma Intelligence 23:18 Tue, 09 Jun
Cine este femeia care conduce afacerile gigantului farma Novartis din România Business Magazin 06:33 Tue, 09 Jun
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 Novartis (Press Release) 08:53 Mon, 08 Jun
Novartis reports positive results from Phase III ALIGN trial for IgAN Clinical Trials Arena 10:44 Fri, 05 Jun
Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy RTT News 12:51 Thu, 04 Jun
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years Novartis (Press Release) 11:29 Thu, 04 Jun
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients Novartis (Press Release) 16:38 Wed, 03 Jun
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture Pharmaceutical Technology 17:13 Tue, 02 Jun
Novartis Pluvicto And Actinium Program Advance Radioligand Therapy In Prostate Cancer RTT News 09:46 Mon, 01 Jun
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases Novartis (Press Release) 06:30 Mon, 01 Jun
Experimental Novartis radiopharma drug shows promise in early study The Tribune, California 12:48 Sun, 31 May
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study The Times of India 12:40 Sun, 31 May
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength Novartis (Press Release) 06:35 Tue, 26 May
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA Novartis (Press Release) 06:46 Thu, 21 May
Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims FiercePharma 21:28 Mon, 18 May
